Synthetic tumor-specific antigenic peptides with a strong affinity to HLA-A2 elicit anti-breast cancer immune response through activating CD8+ T cells
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
Researches on tumor-associated antigen have become a hot target in immunotherapy, but it stagnated in the pre-clinical/clinical stages. Here, we developed a series of MAGE-A1-restricted antigenic peptides, which exhibited prominent inhibiting effect on specific breast cancer. Peptides were synthesized by Fmoc solid phase method and analyzed by online servers. The stability and affinity to HLA-A2 was assessed by inverted fluorescence and flow cytometry qualitatively and quantitatively. In vitro effect on dendritic cells (DCs) maturation was observed by morphology and surface markers. The secretion of IFN-γ in the supernatant was detected by co-incubation of DCs loaded with as-synthesized peptides and CD8+ T lymphocytes. The specific immune response was evaluated against 4 cell lines, and the response in MCF-7 xenografted BALB/c nude mice were further assessed. Most of the derived peptides, especially I-6, showed great HLA-A2 binding ability. Compared with cytokines, I-6 significantly induced DCs maturation and promoted CD8+ T lymphocytes activation. Additionally, it is more specific for the lethality of MAGE & HLA-A2 double positive cells compared with others. We successfully developed I-6 with a high affinity to HLA-A2 which could induce strong specific immune response. It could be a potential candidate for breast cancer immunotherapy, which deserves further studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:189 |
|---|---|
| Enthalten in: |
European journal of medicinal chemistry - 189(2020) vom: 01. März, Seite 112051 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shi, Wei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Affinity |
|---|
| Anmerkungen: |
Date Completed 30.10.2020 Date Revised 30.10.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejmech.2020.112051 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM305655817 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM305655817 | ||
| 003 | DE-627 | ||
| 005 | 20231225121643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejmech.2020.112051 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1018.xml |
| 035 | |a (DE-627)NLM305655817 | ||
| 035 | |a (NLM)31968280 | ||
| 035 | |a (PII)S0223-5234(20)30018-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shi, Wei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthetic tumor-specific antigenic peptides with a strong affinity to HLA-A2 elicit anti-breast cancer immune response through activating CD8+ T cells |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.10.2020 | ||
| 500 | |a Date Revised 30.10.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Researches on tumor-associated antigen have become a hot target in immunotherapy, but it stagnated in the pre-clinical/clinical stages. Here, we developed a series of MAGE-A1-restricted antigenic peptides, which exhibited prominent inhibiting effect on specific breast cancer. Peptides were synthesized by Fmoc solid phase method and analyzed by online servers. The stability and affinity to HLA-A2 was assessed by inverted fluorescence and flow cytometry qualitatively and quantitatively. In vitro effect on dendritic cells (DCs) maturation was observed by morphology and surface markers. The secretion of IFN-γ in the supernatant was detected by co-incubation of DCs loaded with as-synthesized peptides and CD8+ T lymphocytes. The specific immune response was evaluated against 4 cell lines, and the response in MCF-7 xenografted BALB/c nude mice were further assessed. Most of the derived peptides, especially I-6, showed great HLA-A2 binding ability. Compared with cytokines, I-6 significantly induced DCs maturation and promoted CD8+ T lymphocytes activation. Additionally, it is more specific for the lethality of MAGE & HLA-A2 double positive cells compared with others. We successfully developed I-6 with a high affinity to HLA-A2 which could induce strong specific immune response. It could be a potential candidate for breast cancer immunotherapy, which deserves further studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Affinity | |
| 650 | 4 | |a Antigenic peptides | |
| 650 | 4 | |a HLA-A2 | |
| 650 | 4 | |a MAGE-A1 | |
| 650 | 4 | |a Specific immune response | |
| 650 | 7 | |a HLA-A2 Antigen |2 NLM | |
| 650 | 7 | |a MAGEA1 protein, human |2 NLM | |
| 650 | 7 | |a Melanoma-Specific Antigens |2 NLM | |
| 650 | 7 | |a Neoplasm Proteins |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 700 | 1 | |a Qiu, Qianqian |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Zhenzhen |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Weiwei |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Ziying |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Wenlong |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Hai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of medicinal chemistry |d 1994 |g 189(2020) vom: 01. März, Seite 112051 |w (DE-627)NLM106608835 |x 1768-3254 |7 nnns |
| 773 | 1 | 8 | |g volume:189 |g year:2020 |g day:01 |g month:03 |g pages:112051 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejmech.2020.112051 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 189 |j 2020 |b 01 |c 03 |h 112051 | ||